Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)


Creative Commons License

Drake M. J., MacDiarmid S., Chapple C. R., ESEN A. A., Athanasiou S., Cambronero Santos J., ...Daha Fazla

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.71, sa.5, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 71 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1111/ijcp.12944
  • Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims/objectives: In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and beta(3)-adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic effect on the cardiovascular (CV) system requires investigation.